Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 13
Submit an article Journal homepage
294
Views
24
CrossRef citations to date
0
Altmetric
Letters to the Editor

Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies

Daniel Rea Department of Medical Oncology, Centre Hospitalier Antibes Juan-les-Pins, Antibes, France;b Department of Medical Oncology, Centre Antoine Lacassagne, Nice, FranceCorrespondence[email protected]
,
Jérôme Barrièrec Department of Medical Oncology, Clinique Saint-Jean, Cagnes-sur-Mer, France
,
Emmanuel Chamoreyd Department of Biostatistics and Epidemiology, Centre Antoine Lacassagne, Nice, FranceORCID Iconhttps://orcid.org/0000-0002-6841-4571
ORCID Icon,
Margaux Delforgee Department of Pharmacy, Centre Hospitalier Antibes Juan-les-Pins, Antibes, France
,
Lauris Gastaudb Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France
,
Emmanuel Petitc Department of Medical Oncology, Clinique Saint-Jean, Cagnes-sur-Mer, France
,
Axel Chaminadec Department of Medical Oncology, Clinique Saint-Jean, Cagnes-sur-Mer, France
,
Benjamin Verrièree Department of Pharmacy, Centre Hospitalier Antibes Juan-les-Pins, Antibes, France
&
Frédéric Peyradeb Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France
 show all
Pages 3308-3310 | Received 20 May 2021, Accepted 10 Jul 2021, Published online: 26 Jul 2021

Citations (24)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Simone Claudiani, Eleanor L. Parker, Dragana Milojkovic, Carolina Rosadas, Afzal Khan, Ksenia Katsanovskaja, Federica Marchesin, Maryam Khan, Richard S. Tedder, Andrew J. Innes, Myra O. McClure & Jane F. Apperley. (2022) Long-term persistence of natural anti-SARS-CoV-2 antibodies and mild impact of SARS-CoV-2 infection in CML patients: results from a seroprevalence study. Leukemia & Lymphoma 63:6, pages 1504-1507.
Read now

Articles from other publishers (23)

Erica Franceschini, Mariachiara Pellegrino, Vera Todisco, Giovanni Dolci, Francesca Bettelli, Marianna Meschiari, Andrea. Bedini, Giulia Fregni-Serpini, Antonella Grottola, Giovanni Guaraldi, Monica Pecorari, Mario Sarti, Mario Luppi, Carlo Federico Perno & Cristina Mussini. (2023) Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab. Infection.
Crossref
Efstathia Liatsou, Ioannis Ntanasis-Stathopoulos, Stavros Lykos, Anastasios Ntanasis-Stathopoulos, Maria Gavriatopoulou, Theodora Psaltopoulou, Theodoros N. Sergentanis & Evangelos Terpos. (2023) Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis. Cancers 15:8, pages 2266.
Crossref
Alessandra Oliva, Francesco Cogliati Dezza, Flavia Petrucci, Francesco Eugenio Romani, Matteo Morviducci, Flavio Marco Mirabelli, Francesca Cancelli, Emanuele Valeriani, Giulia Marcelli, Francesco Pugliese, Ombretta Turriziani, Paolo Ricci, Mario Venditti, Paolo Palange & Claudio Maria Mastroianni. (2023) Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study. Clinical and Experimental Medicine.
Crossref
Maxime Teisseyre, Daisy Graça, Daniel Re, Marion Cremoni, Sylvia Benzaken, Kévin Zorzi, Céline Fernandez, Vincent L M Esnault, Jérôme Barrière, Vesna Brglez & Barbara Seitz-Polski. (2023) Humoral and cellular responses after a third dose of SARS-CoV-2 mRNA vaccine in patients with glomerular disease. Nephrology Dialysis Transplantation 38:1, pages 249-251.
Crossref
Elisabetta Metafuni, Antonella Cingolani, Massimo Fantoni, Patrizia Chiusolo, Sabrina Giammarco, Federica Sorà, Eugenio Galli, Stefan Hohaus, Francesco D’Alò, Silvia Bellesi, Elena Maiolo, Eleonora Alma, Luca Laurenti, Idanna Innocenti, Francesco Autore, Maria Assunta Limongiello, Rosaria Santangelo, Simona Marchetti, Rosalba Ricci & Simona Sica. (2023) Safety and efficacy of SARS‐Cov2 neutralizing monoclonal antibodies after stem cell transplant or CAR‐T cell infusion. Hematological Oncology.
Crossref
Noppacharn Uaprasert, Palada Pitakkitnukun, Nuanrat Tangcheewinsirikul, Thita Chiasakul & Ponlapat Rojnuckarin. (2022) Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis. Blood Cancer Journal 12:12.
Crossref
Helen Kakkassery, Esme Carpenter, Piers E.M. Patten & Sheeba Irshad. (2022) Immunogenicity of SARS-CoV-2 vaccines in patients with cancer. Trends in Molecular Medicine 28:12, pages 1082-1099.
Crossref
Bin Ni, Ahmad Yanis, Kevin Dee, James D. Chappell, Daniel E. Dulek, Adetola A. Kassim, Carrie L. Kitko, Lora D. Thomas & Natasha Halasa. (2022) SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies. Blood Reviews 56, pages 100984.
Crossref
Kefu Tang, Zhiying Wei & Xi Wu. (2022) Impaired serological response to COVID‐19 vaccination following anticancer therapy: A systematic review and meta‐analysis. Journal of Medical Virology 94:10, pages 4860-4868.
Crossref
Maryam Noori, Shadi Azizi, Farhan Abbasi Varaki, Seyed Aria Nejadghaderi & Davood Bashash. (2022) A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies. International Immunopharmacology 110, pages 109046.
Crossref
Yusuke Ito, Akira Honda & Mineo Kurokawa. (2022) COVID-19 mRNA Vaccine in Patients With Lymphoid Malignancy or Anti-CD20 Antibody Therapy: A Systematic Review and Meta-Analysis. Clinical Lymphoma Myeloma and Leukemia 22:8, pages e691-e707.
Crossref
Petra Langerbeins & Michael Hallek. (2022) COVID-19 in patients with hematologic malignancy. Blood 140:3, pages 236-252.
Crossref
William Wang, David C. Kaelber, Rong Xu & Nathan A. Berger. (2022) Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US Between December 2020 and November 2021. JAMA Oncology 8:7, pages 1027.
Crossref
Lorenz Schubert, Maximilian Koblischke, Lisa Schneider, Edit Porpaczy, Florian Winkler, Ulrich Jaeger, Stephan Blüml, Helmuth Haslacher, Heinz Burgmann, Judith H. Aberle, Stefan Winkler & Selma Tobudic. (2022) Immunogenicity of COVID-19 Vaccinations in Hematological Patients: 6-Month Follow-Up and Evaluation of a 3rd Vaccination. Cancers 14:8, pages 1962.
Crossref
K. A. Sychevskaya & S. K. Kravchenko. (2022) Monoclonal anti-CD20 antibodies in lymphomas therapy during the COVID-19 pandemic: pro and contra. Oncohematology 17:2, pages 95-106.
Crossref
Joanne S. K. Teh, Julien Coussement, Zoe C. F. Neoh, Tim SpelmanSmaro LazarakisMonica A. Slavin & Benjamin W. Teh. (2022) Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis. Blood Advances 6:7, pages 2014-2034.
Crossref
Paz Beatriz Tabilo Valenzuela, Gabriela Flores Balter, Gustavo Saint-Pierre Contreras, Daniel Conei Valencia, Catalina Moreno Calderón, Constanza Bohle Venegas, Marcia Guajardo Rivera, Francisco Silva Ojeda & Maria Jesus Vial Covarrubias. (2022) Cellular Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination Schemes Authorized by the Chilean Ministry of Health in January 2022. Life 12:4, pages 534.
Crossref
Suranjith L Seneviratne, Pamodh Yasawardene, Widuranga Wijerathne & Buddhika Somawardana. (2022) COVID-19 vaccination in cancer patients: a narrative review. Journal of International Medical Research 50:3, pages 030006052210861.
Crossref
Daniel Re, Barbara Seitz-Polski, Vesna Brglez, Michel Carles, Daisy Graça, Sylvia Benzaken, Stéphane Liguori, Khaled Zahreddine, Margaux Delforge, Béatrice Bailly-Maitre, Benjamin Verrière, Emmanuel Chamorey & Jérôme Barrière. (2022) Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies. Nature Communications 13:1.
Crossref
Carlo Visco, Luigi MarcheselliRoberto Mina, Marianna SassoneAnna GuidettiDomenico Penna, Chiara Cattaneo, Valentina Bonuomo, Alessandro BuscaAndrés José María Ferreri, Riccardo BrunaLuigi PetrucciRoberto CairoliMarco SalviniLorenza BertùMarco LadettoSofia PilerciAntonello Pinto, Safaa RamadanFrancesco MarchesiMichele CavoLuca ArcainiElisa CovielloAlessandra RomanoPellegrino MustoMassimo Massaia, Nicola FracchiollaMonia MarchettiAnnamaria ScattolinMaria Chiara TisiAntonio CuneoMatteo Della Porta, Livio Trentin, Marco Turrini, Filippo GherlinzoniAgostino TafuriSara Galimberti, Monica Bocchia, Valeria CardinaliDaniela Cilloni, Alessandro CorsoDaniele ArmientoLuigi Rigacci, Elettra Ortu La BarberaCarlo Gambacorti-Passerini, Giuseppe VisaniDaniele Vallisa, Adriano Venditti, Carmine SelleriAnnarita ConconiPatrizia TosiFrancesco Lanza, Anna Candoni, Mauro Krampera, Paolo Corradini, Francesco PassamontiFrancesco Merli. (2022) A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. Blood Advances 6:1, pages 327-338.
Crossref
Deniz C. Guven, Taha K. Sahin, Saadettin Kilickap & Fatih M. Uckun. (2021) Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review. Frontiers in Oncology 11.
Crossref
Lindsey Wang, Nathan A. Berger & Rong Xu. (2021) Risks of SARS-CoV-2 Breakthrough Infection and Hospitalization in Fully Vaccinated Patients With Multiple Myeloma. JAMA Network Open 4:11, pages e2137575.
Crossref
Josef Singer, Nguyen-Son Le, Daniel Mattes, Valerie Klamminger, Klaus Hackner, Nicole Kolinsky, Michaela Scherb, Peter Errhalt, Gudrun Kreye, Martin Pecherstorfer, Sonia Vallet & Klaus Podar. (2021) Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients. Cancers 13:17, pages 4312.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.